A Sequential-Cohort, Double-Blind, Placebo-Controlled, Multiple Ascending Oral Dose Study of the Safety and Pharmacokinetics of BTA-C585 in Healthy Volunteers

Trial Profile

A Sequential-Cohort, Double-Blind, Placebo-Controlled, Multiple Ascending Oral Dose Study of the Safety and Pharmacokinetics of BTA-C585 in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Jan 2017

At a glance

  • Drugs Enzaplatovir (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms MAD
  • Sponsors Biota Pharmaceuticals
  • Most Recent Events

    • 21 Mar 2016 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
    • 26 Feb 2016 According to Biota Pharmaceuticals media release, the company announced top-line safety and pharmacokinetic (PK) data from the Phase 1 trial of BTA585 for the treatment and prevention of RSV infections.
    • 26 Feb 2016 Results presented in the Biota Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top